Los Angeles Capital Management LLC Has $19.28 Million Stock Position in United Therapeutics Corporation $UTHR

Los Angeles Capital Management LLC lowered its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 31.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 42,510 shares of the biotechnology company’s stock after selling 19,081 shares during the period. Los Angeles Capital Management LLC’s holdings in United Therapeutics were worth $19,280,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Torren Management LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management lifted its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 614,543 shares of company stock valued at $346,728,395 over the last quarter. 8.60% of the stock is currently owned by insiders.

United Therapeutics Price Performance

Shares of UTHR stock opened at $549.87 on Monday. The business’s 50 day simple moving average is $568.23 and its 200 day simple moving average is $519.16. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market capitalization of $23.34 billion, a PE ratio of 20.30, a PEG ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the company earned $6.63 earnings per share. The business’s revenue was down 1.6% on a year-over-year basis. As a group, research analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on UTHR shares. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Cantor Fitzgerald boosted their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.